Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Inizio leaders featured in Forbes’ ‘Voices of Oncology’ to drive innovation in cancer care

September 24, 2025 |  

Inizio experts contribute to Forbes’ Voices of Oncology, highlighting our commitment to driving innovation in cancer care through advanced data analytics, cross-sector collaboration, and real-world impact for patients.

Voices-of-Oncology-Inizio

With over 30 years of deep-rooted expertise in oncology, we partner with our clients at each pivotal moment in their journey, unlocking value through a connected suite of capabilities. Today, we’re proud to announce that a number of our leaders in Inizio have been featured in Forbes’ Voices of Oncology, a collaboration that reflects our commitment to advancing cancer care.

Launching September 9, the ‘Voice of Innovation Partners’ chapter in Forbes’ ‘Voices of Oncology’ features contributions from:

Accelerating innovation in oncology through collaboration, data & technology

The ‘Voice of Innovation Partners’ chapter explores how innovation partners like Inizio harness advanced data analytics, cutting-edge technology, and cross-sector collaboration to:

  • Simplify complex challenges in oncology
  • Enhance decision-making across the cancer care continuum
  • Improve patient outcomes through real-world impact

The book is a powerful collection of insights from global experts and thought leaders, offering a shared perspective on how we can work better together to shape the future of oncology. Voices of Oncology is an initiative of the Oncology Voice Network (OVN), a new platform built to spark connection, share knowledge, and amplify solutions across pharma, biotech, academia, and patient advocacy.

Pre-order now: Forbes’ Voices of Oncology

Available to pre-order now via Amazon – explore the Voices of Oncology here. If you’re looking for a partner who can turn knowledge into action and accelerate the journey from breakthrough science to real-world impact, learn more about us.

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Pegasus’s Approach to Measurement Wins 3 Gold’s at 2014 AMEC International Summit in Amsterdam

Pegasus, the UK’s leading independent health communications consultancy, added three awards to its 2014 portfolio at last weekend’s AMEC International Summit 2014 in Amsterdam

Pegasus Crowned Health Consultancy of the Year at 2014 Sabre Emea Awards

Brighton consultancy adds top honour to its award wins

Pegasus shortlisted for ‘Consultancy of the year’ at 2014 Communique Awards

Brighton-based independent healthcare specialist looks to add award to growing list of accolades

Pegasus Moves to Brighton

Top UK Healthcare Communications Consultancy Moves to Brighton

Warehousing of HCV patients reaches new high

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...

The Difficulties of Living with Depression Don’t End with the Illness Itself

This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.

Patient Power: Too Much of a Good Thing?

Mary Assimakopoulos, reveals findings from the company’s Therapy Watch market research data, investigating patient behaviour in Crohn’s Disease and discusses how pharma can benefit from improved patient understanding